Stock Evaluator: Biomea Fusion, Inc. (BMEA)

Biomea Fusion, Inc. BMEA

$0.59 0.06 11.02%
November 19, 2026 4:00:00 PM EST November 10, 2021 Volume: 944,789
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.

Commentary & Analysis


Financial Summary

Share Statistics BMEA Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $38.5 $213.9 15%
Shares Out (Mil) 72.6 55.4 55%
Institutional Ownership 86.5% 93.3% 54%
Float (Mil) 67.7 40.6 53%
Beta -0.14 0.98 3%
Avg Daily Volume (000s) 963 597 68%
Price Change
(52-week)
(54.3%) 40.9% 18%
Growth BMEA Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 13.2% na
Net Income (5yr) (63.4%) (10.7%) 5%
EPS (5yr) (18.6%) 15.5% 15
Dividends (5yr) na 0.0% na
Cash Flow (5yr) (15.0%) (15.7%) 52%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 3 2 4
Current EPS ($0.178) ($0.631) ($0.853)
Month Ago EPS ($0.270) ($0.947) ($0.941)
# Rev Up 1 1 1
# Rev Down 0 0 0
Three Months Ago EPS ($0.270) ($0.842) ($0.941)
Year/Year Chg 109.4% (46.7%) (12.1%)
Financials BMEA Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) na $39 na
Net Income (TTM) (Mil) ($22) ($44) 23%
EPS (TTM) ($0.309) ($1.400) 30%
Operating Cash Flow (TTM) (Mil) ($44) ($34) 10%
Net Cash Flow (TTM) (Mil) na $-0 na
Long-Term Debt (Q1) (Mil) $0 $4 0%
Enterprise Value (Q1) (Mil) $10 $135 9%
Valuation BMEA Industry
Median
Percentile
(All Stocks)
P/B 5.30 1.97 82%
P/E na 17.6 na
Dividend Yield na 0.0% na
PEG (5yr hist) na 0.8 na
Ratios BMEA Industry
Median
Percentile
(All Stocks)
Gross Margin na 67.9% na
Net Margin na (50.8%) na
ROA (53.6%) (47.5%) 10%
ROE (192.3%) (51.9%) 4%
Liabilities to Assets 73.0% 29.7% 69%
F-Score 3 3 18%

Biomea Fusion, Inc. did not pass any screens on 11/18/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors